Pharming Group (NASDAQ:PHAR – Get Free Report) and Briacell Therap (NASDAQ:BCTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Risk & Volatility
Pharming Group has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Pharming Group and Briacell Therap, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharming Group | 1 | 1 | 3 | 0 | 2.40 |
| Briacell Therap | 1 | 0 | 0 | 0 | 1.00 |
Institutional and Insider Ownership
0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Pharming Group and Briacell Therap’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharming Group | 3.30% | 4.64% | 2.55% |
| Briacell Therap | N/A | -153.53% | -129.26% |
Valuation & Earnings
This table compares Pharming Group and Briacell Therap”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharming Group | $376.13 million | 2.53 | $2.85 million | $0.16 | 84.19 |
| Briacell Therap | N/A | N/A | -$26.31 million | ($7.92) | -0.47 |
Pharming Group has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Summary
Pharming Group beats Briacell Therap on 11 of the 13 factors compared between the two stocks.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
